Opto’s subsidiary EuroCor becomes first ever to receive CE accreditation for DIOR - a drug coated balloon dilation catheter

Bangalore, February 8, 2007: EuroCor Life Sciences, a wholly-owned subsidiary of Opto Circuits (India) Ltd. (OCI), a leading manufacturer of healthcare devices, has received CE approval for marketing and sale of DIOR, a paclitaxel-eluting balloon dilation catheter used in angioplasty procedures.

Expressing delight on the development, Vinod Ramnani, Chairman & Managing Director, OCI, said: “We are the world’s first company to be awarded a CE Mark Approval for a drug-eluting balloon dilation catheter. Obtaining this approval allows EuroCor to sell DIOR in the Europe Union, the Far East, the Middle East, Latin America and Asia. It also opens up new vistas to the EuroCor range of products. We have already increased our production so as to meet the new demand and DIOR will be available immediately.”

Dior can be effectively used for the successful treatment of coronary in-stent restenosis and treatment of small-diameter coronary artery lesions (that are less than 2.5mm in diameter).

Re-stenosis is usually treated with placing another Stent within the existing Stent, at times, resulting in even higher re-stenosis. Hence, the Stented patient may require being accessible for additional treatments. DIOR is a unique, problem and life saving catheter that enables the Cardiologist to treat in-stent restonosis without placing another Stent into the Stent and thus rendering the patient safe for further interventions, if needed.

OCI and EuroCor have an aggressive marketing strategy to promote DIOR through already appointed and established 33 distributors across 29 countries.